Agios Pharmaceuticals, Inc. (AGIO) NASDAQ
28.00
-1.4(-4.76%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
28.00
-1.4(-4.76%)
Currency In USD
| Previous Close | 29.4 |
| Open | 29.1 |
| Day High | 29.25 |
| Day Low | 27.51 |
| 52-Week High | 46 |
| 52-Week Low | 22.24 |
| Volume | 853,635 |
| Average Volume | 1.05M |
| Market Cap | 1.67B |
| PE | -3.86 |
| EPS | -7.26 |
| Moving Average 50 Days | 29.53 |
| Moving Average 200 Days | 32.27 |
| Change | -1.4 |
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
GlobeNewswire Inc.
Mar 02, 2026 12:00 PM GMT
PYRUKYND is the only medicine approved in the UAE for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia NewBridge Pharmaceuticals, a regional specialty company, will continue to manage commercialization of PYR
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET
GlobeNewswire Inc.
Jan 26, 2026 12:00 PM GMT
CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company wil
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
AQVESME™ (mitapivat) U.S. commercial launch in thalassemia underway following December 2025 FDA approvalPre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter of 2026, with planned U.S. regulatory submission to fo